Dear list members,
I thought this might be of interest. And in case you wondered, I
still believe in the tooth fairy, too...
Judith.
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Sept. 11, 2000-- PharmaPrint
Inc. (OTCBB: PPRT) Monday announced the issuance of two additional
patents.
The U.S. Patent and Trademark Office issued Patent Number 6,113,907
covering the method of the PharmaPrint(TM) Process in the
production of high quality St. John's Wort preparations. The
company had previously announced a U.S. Patent granted for saw
palmetto. in addition, the company announced that the Australian
Patent Office issued Patent No. 716,155 which provides broad patent
protection for the PharmaPrint(TM) Process in Australia.
"We're encouraged by the issuance of patents for saw palmetto, St.
John's Wort and the Australian patent across all botanicals," said
Steven Bowman, chief executive officer of PharmaPrint. "With
the acceptance of these patents both domestically and abroad, it is
clear that claims covering the appropriate standardization method for
botanicals is attainable. These patents cover two botanicals
well-known to the American consumer and help protect our development
of these botanicals for pharmaceutical use. We're currently pursuing
additional claims for saw palmetto and St. John's
Wort," Bowman said.
"Public skepticism about the current standardization method of herbs
is well-founded," Bowman added. "These patents identify a method of
standardization for complex botanicals allowing the
development of a pharmaceutical grade saw palmetto or St. John's
Wort. Additionally, our patents provide a certain level of protection
from competitors of the company's dietary supplement and
pharmaceutical versions of saw palmetto and St. John's Wort."
About PharmaPrint
PharmaPrint is a developer of nutraceuticals -- plant derived
products that may offer therapeutic benefits, but are not regulated
by the Food and Drug Administration (FDA) and botanical
pharmaceuticals developed for approval through the FDA process. The
company's proprietary PharmaPrint(TM) Process technology enables the
precise identification and consistent replication of the active
ingredients from these extracts that are scientifically believed to
provide the desired health benefits. PharmaPrint Inc. intends to
commence in the manufacture of these products or to enter into
agreement with third parties to manufacture these products in the
future. For more information, contact the company's Web site at
www.pharmaprint.com.
This news statement contains forward-looking statements regarding
potential future events and developments affecting the business of
PharmaPrint Inc. These forward-looking statements involve unknown
risks, uncertainties or other factors not under the control
of PharmaPrint Inc., which may cause its actual results, performance
or achievements to be materially different from the future results,
performance or achievements or other expectations expressed
or implied by these forward-looking statements. For further
information, see the company's registration statement on Form S-3,
dated July 6, 1999; the company's Annual Report on Form 10-K, for the
year ended March 31, 2000; and the company's Quarterly Report on Form
10-Q, for the quarter ended June 30, 2000.
Contact:
PharmaPrint Inc., Newport Beach
Donna Slade, 949/794-7778
**********************************************
--
The silver-list is a moderated forum for discussion of colloidal silver.
To join or quit silver-list or silver-digest send an e-mail message to:
[email protected] -or- [email protected]
with the word subscribe or unsubscribe in the SUBJECT line.
To post, address your message to: [email protected]
Silver-list archive: http://escribe.com/health/thesilverlist/index.html
List maintainer: Mike Devour <[email protected]>
